La Chemioterapia Del Carcinoma Polmonare a Cellule Non Piccole in Fase Avanzata. Dall'uso esclusivo della “P” all'interpretazione quantitativo-probabilistica dei dati metanalitici
Restricted accessResearch articleFirst published online July, 2004
La Chemioterapia Del Carcinoma Polmonare a Cellule Non Piccole in Fase Avanzata. Dall'uso esclusivo della “P” all'interpretazione quantitativo-probabilistica dei dati metanalitici
ChuteJ.P., ChenT., FeigalE., SimonR., JohnsonB.E.: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol, 17: 1794–1801, 1999.
2.
BreathnachO.S., FreidlinB., ConleyB., GreenM.R., JohnsonD.H., GandaraD.R., O'ConnellM., ShepherdF.A., JohnsonB.E.: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol, 19: 1734–1742, 2001.
3.
Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 311: 899–909, 1995.
4.
Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer.Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol, 15: 2996–3018, 1997.
5.
WozniakA.J., CrowleyJ.J., BalcerzakS.P., WeissG.R., SpiridonidisC.H., BakerL.H., AlbainK.S., KellyK., TaylorS.A., GandaraD.R., LivingstonR.B.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol, 16: 2459–2465, 1998.
6.
PawelJvo, RoemelingRvo: Survival benefit from Tirazon™ (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT I trial. Proc ASCO1998, abstr 1749.
7.
SandlerA.B., NemunaitisJ., DenhamC., von PawelJ., CormierY., GatzemeierU., MattsonK., ManegoldC., PalmerM.C., GregorA., NguyenB., NiyikizaC., EinhornL.H.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 18: 122–130, 2000.
8.
GatzemeierU., von PawelJ., GottfriedM., ten VeldeG.P., MattsonK., De MarinisF., HarperP., SalvatiF., RobinetG., LucentiA., BogaertsJ., GallantG.: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 18: 3390–3399, 2000.
9.
CrinòL., ScagliottiG.V., RicciS., De MarinisF., RinaldiM., GridelliC., CeribelliA., BiancoR., MarangoloM., Di CostanzoF., SassiM., BarniS., RavaioliA., AdamoV., PortaloneL., CrucianiG., MasottiA., FerraraG., GozzelinoF., TonatoM.: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol, 17: 3522–3530, 1999.
10.
BonomiP., KimK., FaircloughD., CellaD., KuglerJ., RowinskyE., JiroutekM., JohnsonD.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol, 18: 623–631, 2000.
11.
Le ChevalierT., BrisgandD., SoriaJ.C., DouillardJ.Y., PujolJ.L., RuffieP., AberolaV., CigolariS.: Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist, 6(suppl. 1): 8–11, 2001.
12.
RuddR.M., GowerN.H., JamesL.E., GregoryW., EisenT., LeeS.M., HarperP.G., SpiroS.G.: Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc ASCO2002, abstr 1164.
13.
MeloM.J., BarradasP., CostaA., CristovaoM., AlvesP.: Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proc ASCO2002, abstr 1205.
14.
DelbaldoC., SyzN., MichielsS., Le ChevalierT., PignonJ-P: Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature. Proc ASCO2003, abstr 2507.
15.
EttingerD.S.: Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?Oncologist, 7: 226–233, 2002.
16.
Socinski MA, Morris DE, Masters GA, Lilen-baum R, American College of Chest Physicians:Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 123(1 Suppl): 226S–243S, 2003.
17.
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr., Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, American Society of Clinical Oncology:American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol, 22: 330–353, 2004.
18.
CardenalF., Lopez-CabrerizoM.P., AntonA., AlberalaV., MassutiB., CarraioA., BarnetoI., LomasM., GarciaM., LianesP., MontalarJ., VadellC., Gonzalez-LarribaJ.L., NguyenB., ArtalA., RoseliR.: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 17: 12–18, 1999.
19.
DansonS., ClemonsM., MiddletonM., O'ByrneK., HassanJ., AndersonH., BurtP., StoutR., SwindellR., DowdI., BeresfordC., ThatcherN.: A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO2001, abstr 1285.
20.
ChangJ.W.C., LiawC-C, ChenC-H, YangC-T, LinM-C, TsaoT.C.Y.: Randomized phase II study of vinorelbine plus cisplatinum versus gemcitabine plus cisplatinum in advanced non-small cell lung cancer: a preliminary result. Proc ASCO2001, abstr 1339.
21.
Cornelia P, Panza N, Manzione L, De Cataldis G, Cioffi R, Maiorino L, Lorusso V, Lamberti A, Micillo E, Natale M, Bilancia D, Nicolella G, Di Nota A, Mancarella S, Frasci G, Cornelia G, Southern Italy Cooperative Oncology Group Study:Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine vs either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small-cell lung cancer. A Southern Italy Cooperative Oncology Group Study. Clin Lung Cancer, 1: 202–207, 2000.
22.
GridelliC., ShepherdF., PerroneF., IllianoA., PiantedosiF.V., RobbiatiS.F., ManzioneL., BarberaS., FrontiniL., VeltriE., CigolariS., FindlayB.P., HirshV., SeymourL., BezjakA., GalloC.: GemVin investigators, gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GemVin Investigators and the National Cancer Institute of Canada Clinical Trials Group. Proc ASCO2002, abstr 1165.
23.
ScaglioniG.V., De MarinisF., RinaldiM., CrinòL., GridelliC., RicciS., MatanoE., BoniC., MarangoloM., FaillaG., AltavillaG., AdamoV., CeribelliA., ClericiM., Di CostanzoF., FrontiniL., TonatoM.: Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol, 20: 4285–491, 2002.
24.
SchillerJ.H., HarringtonD., BelaniC.P., LangerC., SandlerA., KrookJ., ZhuJ., JohnsonD.H.: Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346: 92–98, 2002.
25.
ThomasP.A., RobinetG., SylvieG., FournelP., BombaronP., LenaH., PerduD., PerolM., VergnenegreA., SilvaniJ-A, KleisbauerJ-P: Randomized phase II study of carboplatin/gemcitabine versus cisplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) (GFPC 99-01 study). Proc ASCO2002, abstr 1341.
26.
van Meerbeeck JP, Smit EF, Lianes P, Schramel F, Lenz MA, Debruyne C, Giaccone G, European Organization for Research and Treatment of Cancer Lung Cancer Group:A EORTC randomized phase III trial of the three chemotherapy regimens in advanced non-small cell lung cancer. Proc ASCO2001, abstr 1228.
27.
Le ChevalierT., BrownA., NataleR., ScagliottiG., VansteenkisteJ., Van MeerbeeckJ.L., RoseliR., RuddR.M., DansonS., ThatcherN., SchillerJ.: Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis of survival and progression free survival data. Lung Cancer, 41(suppl. 2): 70, 2003.
28.
ParenteB., BarrosoA., CondeS.: A randomized phase III of gemcitabine and carboplatin versus vinorelbine and carboplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 29(suppl. 1): S61.
29.
GrigorescuA.C., DraghiciI.N., NitipirC., GutulescuN., CorlanE.: Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer, 37: 15–16, 2002.
30.
PujolJ.L., CarestiaL., DauresJ.P.: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer, 83: 8–15, 2000.
31.
BucherH.C., GuyattG.H., GriffithL.E., WalterS.D.: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol, 50: 683–691, 1997.
32.
SongF., AltmanD.G., GlennyA.M., DeeksJ.J.: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ, 326: 472, 2003.
33.
FisherL.D., GentM., BullerH.R.: Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J, 141: 26–32, 2001.
34.
RothmannM., LiN., ChenG., ChiG.Y., TempleR., TsouH.H.: Design and analysis of non-inferiority mortality trials in oncology. Stat Med, 22: 239–264, 2003.
35.
KlotzL., SchellhammerP., CarrollK.: A re-assessment of the role of combination therapy in advanced prostate cancer. Br J Urol Int2004, in press.
